MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.breast.2026.104812

Медицинская библиотека · Breast (Edinburgh, Scotland) · 2026

Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant.

Pogoda Katarzyna, Arecco Luca, Lambertini Matteo

СтатьяОбзорПеревод в очереди

Аннотация

Vasomotor symptoms (VMS) have a major impact on quality-of-life in women with hormone receptor-positive breast cancer receiving adjuvant endocrine therapy. As menopause hormone therapy is contraindicated in this setting, effective non-hormonal treatment options are urgently needed. We performed a focused narrative review of neurokinin (NK) receptor antagonists for VMS, including the OASIS-1-4 program for elinzanetant and the SKYLIGHT, MOONLIGHT, and DAYLIGHT programs for fezolinetant, with emphasis on breast cancer-specific data, safety, drug-drug interactions, and selected special populations relevant to oncology practice. Elinzanetant, a dual NK1/NK3 receptor antagonist approved by the European Medicines Agency and the U.S. Food and Drug Administration, provides the first phase III evidence in the specific cohort of patients with breast cancer receiving endocrine therapy. In the OASIS-4 trial, elinzanetant demonstrated rapid and clinically meaningful reductions in moderate-to-severe VMS, with sustained improvements in sleep and menopause-specific quality of life and a favorable tolerability profile without a signal for clinically significant hepatotoxicity. Fezolinetant, a selective NK3 receptor antagonist approved for menopausal VMS in the general population, has shown robust efficacy across multiple phase III trials; however, its use requires liver function monitoring due to hepatotoxicity, and its role in breast cancer survivors remains under investigation. Safety considerations of NK receptor antagonists include their use alongside CDK4/6 inhibitors. With breast cancer-specific data for elinzanetant and ongoing trials of fezolinetant, these agents will change clinical practice by improving symptom control and adherence to adjuvant endocrine therapy overall.

Для цитирования: Pogoda Katarzyna, Arecco Luca, Lambertini Matteo. Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant.. Breast (Edinburgh, Scotland). 2026. DOI: 10.1016/j.breast.2026.104812.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.